Blocking O-Glycan-Protein Interaction Inhibitor Development Service

Blocking O-Glycan-Protein Interaction Inhibitor Development Service

Blocking O-Glycan-Protein Interaction Inhibitor Development Service at CD BioGlyco

Glycans have multiple roles in the viral entry process, and blocking the glycosylation modification of O-glycans using a glycobiological approach effectively inhibits the viral entry process. At CD BioGlyco, we provide blocking O-glycan-protein interaction inhibitor development service.

We provide various types of blocking O-glycan-protein interaction inhibitor development services. At the same time, we also modify, optimize, and evaluate the effect of the inhibitors to ensure that the inhibitors we developed have good inhibitory activity.

  • Inhibitor screening and synthesis
    We provide high-throughput screening of selectin inhibitors based on an oligosaccharide library of sialylated Lewis oligosaccharides or molecules of similar structure. Enzyme-linked immunosorbent assay is utilized to screen molecules from this library for their inhibitory effect on blocking O-glycoprotein-protein interactions. Finally, we optimize the structure and characterize the performance of the screened molecules.
  • Inhibitor activity assessment
    We perform in vitro as well as in vivo experiments using animal models or cellular models to test the activity of inhibitors that provide blocking of O-glycan-protein interactions.

Fig.1 Blocking O-glycan-protein interaction inhibitor development service. (CD BioGlyco)Fig.1 Blocking O-glycan-protein interaction inhibitor development service. (CD BioGlyco)


Technology: Blocking the processing of O-glycans

Journal: eLife

IF: 7.7

Published: 2020

Results: The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its receptor-binding domain (RBD), and its primary receptor angiotensin-converting enzyme 2 (ACE2) are extensively glycosylated. The authors observed that the contribution of N- and O-glycans to Spike-ACE2 binding was minimal. However, these carbohydrates play an important role in regulating viral entry. Blocking N-glycan biosynthesis at the oligomannose stage using a genetic approach and the small molecule kifunensine significantly reduced viral entry into ACE2-expressing HEK293T cells. Blocking O-glycan processing also partially blocked viral entry. Mechanistic studies showed that glycans have multiple roles in viral entry. Among them, inhibition of N-glycan biosynthesis enhanced spike protein hydrolysis. This reduces viral presentation to the RBD, decreases binding to host ACE2, and reduces viral entry. Overall, inhibitors of glycosylation chemistry can be evaluated against coronavirus disease 2019 (COVID-19).


  • The synthesis of O-glycans inhibitor can be used to probe the structure of polysaccharides as well as biological functions such as glycan-protein interactions.
  • The production of O-glycan inhibitors can be used in the development of antiviral drugs.
  • The development of inhibitors that block O-glycans-protein interactions could be used in medical research.


  • We offer our clients multiple routes to O-glycan inhibitor development and are committed to the highest standards to ensure client satisfaction.
  • Our research team is highly specialized and helps our clients solve their challenges in inhibitor development on time.
  • Our R&D team has high-quality technology for inhibitor development.

CD BioGlyco has been dedicated to the Development of Glycosylation Inhibitors for many years and has achieved great progress. We have developed several aspects in the field of O-Glycosylation Inhibitor Development Services. Our team ensures high quality at every step. To learn more about our R&D services, please feel free to contact us.


  1. Yang, Q.; et al. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. eLife. 2020, 9: e61552.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.